Kyndryl Reaffirms Turnaround Case at JP Morgan Conference Amid Market Skepticism

What happened

At the J.P. Morgan conference, Kyndryl management reiterated its FY26 guidance of ~1% constant-currency revenue growth and ~$550M free cash flow, leaning on a record $18.2B in FY25 signings and growing AI/hyperscaler revenue to support the trajectory. However, the market’s doubt is justified: H1 FY26 revenue still declined 1% YoY, and operating cash flow was a paltry $22M, underscoring the lumpy conversion of backlog into cash. The deep value report notes that while margin expansion (adjusted EBITDA ~16%) is real, much of it stems from workforce cuts and non-repeating items, not sustainable mix shift. Kyndryl’s $34B backlog provides a buffer, but elongated sales cycles and deliberate pruning of low-margin contracts delay the growth inflection. For now, the investment thesis hinges on whether FY26 H2 delivery validates management’s targets or proves that the turnaround is running out of steam.

Implication

Near-term, the stock’s ~5.5x EV/EBITDA and ~11x P/E already price in execution risk, but any negative guidance revision or weak FCF could push it toward the $22 bear case. The bull case requires sustained margin expansion above 18% EBITDA and revenue growth above 1%, driven by AI and hyperscaler revenue exceeding $1.8B. Over the next 12 months, Kyndryl must demonstrate that strong signings translate into reported growth and cash generation; otherwise the thesis breaks. The conference presentation likely offered no new catalysts, merely a reaffirmation, so the stock remains a show-me story. For risk-tolerant investors, an attractive entry exists near $25 with a trim above $36, but discipline is required to avoid value traps.

Thesis delta

Management’s presentation at the JP Morgan conference did not introduce new information or alter the investment thesis; it merely reaffirmed existing FY26 targets. The delta is that without concrete progress in H2, the market's skepticism will likely persist, increasing the probability of the bear scenario (flat revenue, FCF stagnation). Investors should treat the stock as a high-risk turnaround with binary outcomes based on H2 delivery.